Proton Pump Inhibitors in Veterinary Medicine

Yavuz, Oğuzhan; Arslan, Handan Hilal

doi:10.3844/ajavsp.2017.132.138

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, administering omeprazole twice daily to healthy dogs for 15 days resulted in quantifiable changes in the gastric, duodenal, and fecal microbiome, accompanied by a significant increase in gastric pH and altered bacterial composition. Lactobacillus bacteria were notably elevated in the duodenum and fecal samples in male dogs during omeprazole therapy without qualitative changes in fecal composition [6,14]. Changes in pharyngeal flora, including Staphylococcus spp., Bacillus spp., and Pasteurella spp.…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Prospective Randomized Controlled Clinical Trial of the Long-Term Effects of Omeprazole on Healthy Dogs

Gil-Vicente,

Martín,

Soler

et al. 2024

Animals

View full text Add to dashboard Cite

The use of omeprazole as a preventive treatment for gastrointestinal ulcers in veterinary medicine has been questioned during previous years. The aim of the present study is to assess the long-term effect of omeprazole on cobalamin and serum gastrin levels in healthy dogs. Eighteen healthy dogs were included: 10 in the control group and 8 in the omeprazole group. Three samples were collected: before starting the treatment (T0), 30 days after the start of treatment (T1), and at 60 days (T2). The mean cobalamin value (ng/L) in the control group was 481.4 (±293.70) at T0, 481.4 (±170.21) at T1, and 513.2 (±174.50) at T2. In the omeprazole group, the values were 424.62 (±161.57) at T0, 454.5 (±160.96) at T1, and 414.87 (±127.90) at T2. No statistically significant changes were detected in cobalamin levels between the three-time period in both study groups. These results agree with previous findings in felines but contrast with human medicine studies. The median gastrin values (pg/mL) in the control group were 62.45 [30.17–218.75] at T0, 76.06 [30.67–199.87] at T1, and 63.02 [35.81–176.06] at T2. The median gastrin value in the omeprazole group was 67.59 [55.96–101.60] at T0, 191.77 [75.31–1901.77] at T1, and 128.16 [43.62–1066.46] at T2. Statistically significant differences were detected (p = 0.008), indicating an increase in gastrin levels after initiating treatment with omeprazole. In conclusion, the increased levels of gastrin observed in this population underscore the importance of conducting a comprehensive clinical assessment to identify potential gastrointestinal disorders, particularly in consideration of the usage of omeprazole as a preventive treatment.

show abstract

Section: Introductionmentioning

confidence: 97%

“…It is metabolized rapidly and completely by the liver, by cytochrome P 450 enzymes (CYP 450 ), and eliminated through the urine [1]. Administration can be either parenteral or enteral, with rapid absorption in the small intestine and peak plasmatic concentrations observed three hours post-administration [6].…”

Section: Introductionmentioning

confidence: 99%

Prospective Randomized Controlled Clinical Trial of the Long-Term Effects of Omeprazole on Healthy Dogs

Gil-Vicente,

Martín,

Soler

et al. 2024

Animals

View full text Add to dashboard Cite

show abstract

Comparative pharmacokinetics of intravenous and subcutaneous pantoprazole in sheep and goats

Fadel,

Łebkowska-Wieruszewskac,

Serih

et al. 2024

The Veterinary Journal

View full text Add to dashboard Cite

Comparative Pharmacokinetics of Intravenous and Subcutaneous Omeprazole in Sheep and Goats

Serih,

Fadel,

Łebkowska‐Wieruszewska

et al. 2024

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Abomasal ulcers are a challenge in animal farming, affecting health, welfare, and productivity. Omeprazole's (OPZ) efficacy in treating these ulcers is known, but data on its pharmacokinetics (PK) in adult goats and sheep are lacking. The purpose of this research was to investigate and contrast OPZ's PK in these animals following a single intravenous (IV, 1 mg/kg) and subcutaneous (SC, 2 mg/kg) doses. Sheep and goats had similar exposure levels for all administration routes, with no significant AUC(0‐∞)D variations. Half‐life was short in both species (sheep: 0.20 h; goats: 0.31 h). Goats had a higher volume of distribution after IV administration. Clearance was rapid, and extraction ratio values were high for both goats and sheep (43% and 30%, respectively). SC administration showed similarities in Cmax and Tmax values between species. Both goats and sheep had high bioavailability (about 80%) levels and comparable mean absorption times (MAT). Despite some PK parameters' variances, systemic exposure to OPZ is similar in sheep and goats. SC administration's high bioavailability suggests it as a convenient field application route. Further investigations are needed to understand OPZ's effectiveness in small ruminants with abomasal ulcers and improve dosing regimens for clinical use.

show abstract

Proton Pump Inhibitors in Veterinary Medicine

Cited by 4 publications

References 36 publications

Prospective Randomized Controlled Clinical Trial of the Long-Term Effects of Omeprazole on Healthy Dogs

Prospective Randomized Controlled Clinical Trial of the Long-Term Effects of Omeprazole on Healthy Dogs

Comparative pharmacokinetics of intravenous and subcutaneous pantoprazole in sheep and goats

Comparative Pharmacokinetics of Intravenous and Subcutaneous Omeprazole in Sheep and Goats

Contact Info

Product

Resources

About